Indeed it isThe fourth poses a good question.
In my opinion, the answer to the question about barriers to entry is both simple and it's not.
In actual fact, there aren't many barriers to entry per se.
This is not a particularly capital intensive business, nor does it require billions in R&D to become established.
Exro isn't a pharmaceutical company working to develop a blockbuster drug. ( For those that might not know, in the pharmaceutical industry a blockbuster drug is one that generates $1 billion or more in annual revenues. )
Exro's advantage lies in the strengths of its proprietary technology.
The company's recent victory in successfully defending itself in a patent infringment case effectively establishes a legal precedent that validates it's ownership of its intellectual property.
In my opinion, the market failed to "recognize" the significance of the court's decision.
Exro's patents are now bulletproof.